Elliot Alex J, Fleming Douglas M
Birmingham Research Unit of the Royal College of General Practitioners, Lordswood House, 54 Lordswood Road, Harborne, Birmingham B17 9DB, UK.
Expert Rev Vaccines. 2008 Mar;7(2):249-58. doi: 10.1586/14760584.7.2.249.
Respiratory infections are one of the leading causes of morbidity and mortality worldwide: influenza and respiratory syncytial virus (RSV) are the predominant pathogens responsible. Annual vaccination and the use of antiviral drugs provides both protection and treatment against influenza, particularly protecting those patients most at risk, including the elderly and individuals with chronic comorbidities. Currently, there are extremely limited options in the protection against RSV infection, making those at-risk patients vulnerable to serious disease, complications and death. This review focuses on recent trends in respiratory illness in the elderly, particularly focusing on the burden of influenza and RSV on hospitalizations and mortality. We discuss the potential benefit of influenza vaccination on these outcomes, including the recent controversial debate over the effectiveness of influenza vaccination.
流感和呼吸道合胞病毒(RSV)是主要致病原。年度疫苗接种和抗病毒药物的使用可为流感提供保护和治疗,尤其能保护那些高危患者,包括老年人和患有慢性合并症的个体。目前,预防RSV感染的选择极其有限,这使得高危患者易患严重疾病、出现并发症并导致死亡。本综述重点关注老年人呼吸道疾病的近期趋势,尤其关注流感和RSV对住院率和死亡率的影响。我们讨论了流感疫苗接种对这些结果的潜在益处,包括近期关于流感疫苗接种有效性的争议性辩论。